AbCellera Biologics Inc. Payments to Acquire Marketable Securities
AbCellera Biologics Inc. (ABCL) reported Payments to Acquire Marketable Securities of $308.18 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-05
- AbCellera Biologics Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $141.88M, a 12.11% increase year-over-year.
- AbCellera Biologics Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $166.31M, a 0.80% increase year-over-year.
- AbCellera Biologics Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $111.34M, a 27.15% decline year-over-year.
- AbCellera Biologics Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $33.16M, a 82.19% decline year-over-year.
- AbCellera Biologics Inc. payments to acquire marketable securities for fiscal 2025 was $436.04M, a 43.01% decline from fiscal 2024.
- AbCellera Biologics Inc. payments to acquire marketable securities for fiscal 2024 was $765.09M, a 25.10% decline from fiscal 2023.
- AbCellera Biologics Inc. payments to acquire marketable securities for fiscal 2023 was $1.02B, a 33.71% increase from fiscal 2022.
- AbCellera Biologics Inc. payments to acquire marketable securities for fiscal 2022 was $763.98M, a 178.10% increase from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $141.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $308.18M 10-Q · filed 2026-08-05 | $419.52M derived: sum of 3 quarters · filed 2026-08-05 | $452.69M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $166.31M 10-Q · filed 2026-05-11 | $277.65M derived: sum of 2 quarters · filed 2026-05-11 | $310.81M derived: sum of 3 quarters · filed 2026-05-11 | $437.36M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $111.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $144.50M derived: sum of 2 quarters · filed 2026-02-24 | $271.05M derived: sum of 3 quarters · filed 2026-08-05 | $436.04M 10-K · filed 2026-02-24 |
| 2025-09-30 | $33.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $159.71M derived: sum of 2 quarters · filed 2026-08-05 | $324.70M 10-Q · filed 2025-11-06 | $477.54M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $126.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $291.54M 10-Q · filed 2026-08-05 | $444.38M derived: sum of 3 quarters · filed 2026-08-05 | $630.62M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $164.99M 10-Q · filed 2026-05-11 | $317.83M derived: sum of 2 quarters · filed 2026-05-11 | $504.07M derived: sum of 3 quarters · filed 2026-05-11 | $680.71M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $152.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $339.08M derived: sum of 2 quarters · filed 2026-02-24 | $515.72M derived: sum of 3 quarters · filed 2026-02-24 | $765.09M 10-K · filed 2026-02-24 |
| 2024-09-30 | $186.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $362.88M derived: sum of 2 quarters · filed 2025-11-06 | $612.25M 10-Q · filed 2025-11-06 | $889.09M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $176.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $426.01M 10-Q · filed 2025-08-07 | $702.84M derived: sum of 3 quarters · filed 2026-02-24 | $918.63M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $249.37M 10-Q · filed 2025-05-08 | $526.21M derived: sum of 2 quarters · filed 2026-02-24 | $741.99M derived: sum of 3 quarters · filed 2026-02-24 | $910.13M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $276.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $492.62M derived: sum of 2 quarters · filed 2026-02-24 | $660.76M derived: sum of 3 quarters · filed 2026-02-24 | $1.02B 10-K · filed 2026-02-24 |
| 2023-09-30 | $215.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $383.92M derived: sum of 2 quarters · filed 2024-11-04 | $744.67M 10-Q · filed 2024-11-04 | $838.23M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $168.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $528.89M 10-Q · filed 2024-08-06 | $622.44M derived: sum of 3 quarters · filed 2025-02-27 | $1.16B derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $360.75M 10-Q · filed 2024-05-07 | $454.30M derived: sum of 2 quarters · filed 2025-02-27 | $990.43M derived: sum of 3 quarters · filed 2025-02-27 | $1.07B derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $93.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $629.68M derived: sum of 2 quarters · filed 2025-02-27 | $712.21M derived: sum of 3 quarters · filed 2025-02-27 | $763.98M 10-K · filed 2025-02-27 |
| 2022-09-30 | $536.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $618.66M derived: sum of 2 quarters · filed 2023-11-02 | $670.43M 10-Q · filed 2023-11-02 | $699.83M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $82.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $134.31M 10-Q · filed 2023-08-03 | $163.70M derived: sum of 3 quarters · filed 2024-02-20 | |
| 2022-03-31 | $51.77M 10-Q · filed 2023-05-04 | $81.17M derived: sum of 2 quarters · filed 2024-02-20 | ||
| 2021-12-31 | $29.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $274.71M 10-K · filed 2024-02-20 | ||
| 2021-09-30 | $245.31M 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |